Anixa Non Currrent Assets Other vs Other Current Liab Analysis
ANIX Stock | USD 3.14 0.16 4.85% |
Anixa Biosciences financial indicator trend analysis is way more than just evaluating Anixa Biosciences prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Anixa Biosciences is a good investment. Please check the relationship between Anixa Biosciences Non Currrent Assets Other and its Other Current Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.
Non Currrent Assets Other vs Other Current Liab
Non Currrent Assets Other vs Other Current Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Anixa Biosciences Non Currrent Assets Other account and Other Current Liab. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Anixa Biosciences' Non Currrent Assets Other and Other Current Liab is -0.17. Overlapping area represents the amount of variation of Non Currrent Assets Other that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Anixa Biosciences, assuming nothing else is changed. The correlation between historical values of Anixa Biosciences' Non Currrent Assets Other and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Currrent Assets Other of Anixa Biosciences are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Non Currrent Assets Other i.e., Anixa Biosciences' Non Currrent Assets Other and Other Current Liab go up and down completely randomly.
Correlation Coefficient | -0.17 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Other Current Liab
Most indicators from Anixa Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Anixa Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.At this time, Anixa Biosciences' Sales General And Administrative To Revenue is fairly stable compared to the past year. Enterprise Value is likely to rise to about 134.2 M in 2024, whereas Selling General Administrative is likely to drop slightly above 4.2 M in 2024.
Anixa Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Anixa Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Anixa Biosciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 9.5M | 36.3M | 30.4M | 25.5M | 29.4M | 30.8M | |
Other Current Liab | 845.8K | 1.1M | 1.7M | 1.8M | 2.0M | 2.1M | |
Total Current Liabilities | 1.2M | 1.3M | 2.0M | 2.0M | 2.3M | 2.4M | |
Total Stockholder Equity | 8.8M | 35.4M | 29.0M | 24.3M | 28.0M | 29.4M | |
Property Plant And Equipment Net | 54.3K | 254.0K | 212K | 166K | 149.4K | 132.1K | |
Net Debt | (6.4M) | (28.9M) | (12.1M) | (740K) | (666K) | (699.3K) | |
Retained Earnings | (191.8M) | (204.8M) | (218.4M) | (228.2M) | (205.4M) | (195.1M) | |
Cash | 6.4M | 29.1M | 12.4M | 915K | 1.1M | 999.6K | |
Non Current Assets Total | 84.3K | 254.0K | 212K | 166K | 190.9K | 181.4K | |
Cash And Short Term Investments | 9.1M | 35.7M | 29.7M | 23.8M | 27.4M | 28.8M | |
Common Stock Shares Outstanding | 22.2M | 28.6M | 30.4M | 31.0M | 35.6M | 37.4M | |
Liabilities And Stockholders Equity | 9.5M | 36.3M | 30.4M | 25.5M | 29.4M | 30.8M | |
Inventory | 1.0 | (2.4M) | (2.6M) | (46K) | (41.4K) | (39.3K) | |
Other Current Assets | 311.6K | 551.6K | 513K | 1.2M | 1.1M | 1.2M | |
Other Stockholder Equity | 200.4M | 239.9M | 247.1M | 252.2M | 290.1M | 304.6M | |
Total Liab | 1.2M | 1.5M | 2.2M | 2.2M | 2.5M | 2.2M | |
Property Plant And Equipment Gross | 54.3K | 254.0K | 212K | 166K | 149.4K | 132.1K | |
Total Current Assets | 9.4M | 36.0M | 30.2M | 25.4M | 29.2M | 30.6M | |
Non Currrent Assets Other | 910.2K | (200.6K) | 30K | (212K) | (243.8K) | (231.6K) | |
Net Receivables | 66.5K | 2.2K | 46K | 270K | 243K | 231.6K | |
Accounts Payable | 232.4K | 136K | 265K | 206K | 185.4K | 176.1K | |
Non Current Liabilities Total | 287.6K | 220.1K | 175K | 123K | 141.5K | 134.4K | |
Common Stock Total Equity | 189.1K | 203.3K | 242.5K | 309K | 278.1K | 264.2K | |
Short Term Investments | 2.6M | 6.6M | 17.3M | 22.9M | 26.4M | 27.7M | |
Common Stock | 242.5K | 300.5K | 309K | 311K | 279.9K | 265.9K | |
Property Plant Equipment | 200.6K | 54.3K | 254.0K | 212K | 243.8K | 256.0K | |
Net Tangible Assets | 5.2M | 8.8M | 35.4M | 29.0M | 33.4M | 35.1M | |
Noncontrolling Interest In Consolidated Entity | (251.4K) | (423.0K) | (497.0K) | (847K) | (762.3K) | (724.2K) | |
Retained Earnings Total Equity | (170.2M) | (181.8M) | (191.8M) | (218.4M) | (196.5M) | (206.4M) | |
Capital Surpluse | 175.4M | 186.8M | 200.4M | 247.1M | 284.2M | 181.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Anixa Stock Analysis
When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.